Get started
China Resources Pharmaceutical Group Ltd.China Resources Pharmaceutical Group Ltd.China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsETFs
Full chart
Full chart

Compare with China Resources Pharmaceutical Group Ltd.



Key stats


Market capitalization
‪29.59 B‬ HKD
Dividend yield (indicated)
4.63%
Price to earnings Ratio (TTM)
6.89
Basic EPS (TTM)
0.70 HKD
Net income (FY)
‪4.39 B‬ HKD
Revenue (FY)
‪292.36 B‬ HKD
Shares float
‪1.82 B‬
Beta (1Y)
0.54

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
‪85.6 K‬
Change (1Y)
‪+12.9 K‬+17.74%
Revenue / Employee (1Y)
‪3.42 M‬ HKD
Net income / Employee (1Y)
‪51.25 K‬ HKD

Details


Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
crpharm.com
Headquarters
Hong Kong
Founded
1938
IPO date
Oct 28, 2016
ISIN
HK0000311099
FIGI
BBG00DZWSDQ5
Identifiers
ISIN HK0000311099
CFI code
ESVUFR
China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. It operates through the following segments: Manufacturing, Distribution, Retail, and Others. The Manufacturing segment handles the research and development, manufacture, and sale of pharmaceutical and healthcare products. The Distribution segment focuses on the distribution, warehousing, logistics, and pharmaceutical supply chain solutions and services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. The Retail segment deals with the operation of retailing of pharmacy stores. The Others segment comprises of property holding. The company was founded in 1938 and is headquartered in Hong Kong.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


159892
ChinaAMC Hang Seng Hong Kong-Listed Biotech Index ETF Units A
Weight0.81%
Market value‪6.54 M‬
JIVE
JPMorgan International Value ETF
Weight0.16%
Market value‪5.36 M‬
520990
INVESCO Great Wall CSI China Reform Hong Kong Connect Central-SOEs High Dividend Yield ETF
Weight0.31%
Market value‪2.58 M‬
FEM
First Trust Emerging Markets AlphaDEX Fund
Weight0.34%
Market value‪2.56 M‬
3069
ChinaAMC Hang Seng Biotech ETF HKD Counter
Weight0.89%
Market value‪2.27 M‬
520500
Huatai-PB Hang Seng Innovative Medicine Exchange Traded Fund Units
Weight0.73%
Market value‪2.01 M‬
UEVM
VictoryShares Emerging Markets Value Momentum ETF
Weight0.91%
Market value‪1.72 M‬
DFEM
Dimensional Emerging Markets Core Equity 2 ETF
Weight0.02%
Market value‪1.68 M‬
513200
E Fund CSI HK Connect Health Care Composite Exchange Traded Fund Units
Weight0.63%
Market value‪1.61 M‬
VIDI
Vident International Equity Strategy ETF
Weight0.35%
Market value‪1.49 M‬
PXH
Invesco RAFI Emerging Markets ETF
Weight0.07%
Market value‪1.33 M‬

Explore more ETFs 

Frequently asked questions


The current price of 3320 is 4.78 HKD — it has decreased by −0.83% in the past 24 hours. Watch China Resources Pharmaceutical Group Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange China Resources Pharmaceutical Group Ltd. stocks are traded under the ticker 3320.
3320 stock has risen by 4.15% compared to the previous week, the month change is a 5.76% rise, over the last year China Resources Pharmaceutical Group Ltd. has showed a −12.13% decrease.
We've gathered analysts' opinions on China Resources Pharmaceutical Group Ltd. future price: according to them, 3320 price has a max estimate of 7.03 HKD and a min estimate of 7.03 HKD. Watch 3320 chart and read a more detailed China Resources Pharmaceutical Group Ltd. stock forecast: see what analysts think of China Resources Pharmaceutical Group Ltd. and suggest that you do with its stocks.
3320 reached its all-time high on Sep 5, 2018 with the price of 13.16 HKD, and its all-time low was 3.18 HKD and was reached on Dec 20, 2021. View more price dynamics on 3320 chart.
See other stocks reaching their highest and lowest prices.
3320 stock is 1.48% volatile and has beta coefficient of 0.54. Track China Resources Pharmaceutical Group Ltd. stock price on the chart and check out the list of the most volatile stocks — is China Resources Pharmaceutical Group Ltd. there?
Today China Resources Pharmaceutical Group Ltd. has the market capitalization of ‪29.97 B‬, it has increased by 3.52% over the last week.
Yes, you can track China Resources Pharmaceutical Group Ltd. financials in yearly and quarterly reports right on TradingView.
China Resources Pharmaceutical Group Ltd. is going to release the next earnings report on Aug 25, 2026. Keep track of upcoming events with our Earnings Calendar.
3320 earnings for the last half-year are 0.34 HKD per share, whereas the estimation was 0.22 HKD, resulting in a 55.00% surprise. The estimated earnings for the next half-year are 0.46 HKD per share. See more details about China Resources Pharmaceutical Group Ltd. earnings.
China Resources Pharmaceutical Group Ltd. revenue for the last half-year amounts to ‪153.25 B‬ HKD, despite the estimated figure of ‪148.89 B‬ HKD. In the next half-year revenue is expected to reach ‪159.99 B‬ HKD.
3320 net income for the last half-year is ‪2.15 B‬ HKD, while the previous report showed ‪2.23 B‬ HKD of net income which accounts for 0.00% change. Track more China Resources Pharmaceutical Group Ltd. financial stats to get the full picture.
Yes, 3320 dividends are paid semi-annually. The last dividend per share was 0.14 HKD. As of today, Dividend Yield (TTM)% is 4.57%. Tracking China Resources Pharmaceutical Group Ltd. dividends might help you take more informed decisions.
China Resources Pharmaceutical Group Ltd. dividend yield was 4.90% in 2025, and payout ratio reached 31.20%. The year before the numbers were 2.58% and 25.38% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jul 22, 2026, the company has ‪85.6 K‬ employees. See our rating of the largest employees — is China Resources Pharmaceutical Group Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. China Resources Pharmaceutical Group Ltd. EBITDA is ‪17.82 B‬ HKD, and current EBITDA margin is 6.09%. See more stats in China Resources Pharmaceutical Group Ltd. financial statements.
Like other stocks, 3320 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade China Resources Pharmaceutical Group Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So China Resources Pharmaceutical Group Ltd. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating China Resources Pharmaceutical Group Ltd. stock shows the sell signal. See more of China Resources Pharmaceutical Group Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.